- Home
- ASG vs CHRS Comparison
ASG vs CHRS Comparison
Compare ASG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASG | CHRS |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.8M | 296.8M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASG | CHRS |
|---|---|---|
| Price | $5.23 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 270.1K | ★ 953.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | ★ N/A | $1.23 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.55 | $0.72 |
| 52 Week High | $5.69 | $2.62 |
Technical Indicators
Market Signals| Indicator | ASG | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.85 | 47.43 |
| Support Level | $5.04 | $1.55 |
| Resistance Level | $5.27 | $1.78 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 93.29 | 32.94 |
Price Performance
Historical ComparisonAbout ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.